Showing 5561-5570 of 7168 results for "".
- Biosimilar Update: FDA Nod for High-Concentration, Citrate-Free Formulation of Humira Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-fda-nod-for-high-concentration-citrate-free-formulation-of-humira-biosimilar/2461740/The U.S. Food and Drug Administration (FDA) has approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar. The FDA granted approval for the treatment of eight conditions: rheumatoid arthritis, juven
- Wayne State University Dermatology Resident Wins Svider Memorial Scholarship Awardhttps://practicaldermatology.com/news/wayne-state-university-dermatology-resident-wins-svider-memorial-scholarship-award/2461737/Kayla St. Claire, M.D., M.B.A., a Wayne State University School of Medicine dermatology resident, has won the Peter Svider Memorial Resident Scholarship Award. The award is presented annually to a graduating resident or fellow in any graduate medical education program in recognition of
- Call for Papers: JMIR Dermatology Special Theme Issue on Teledermatologyhttps://practicaldermatology.com/news/call-for-papers-jmir-dermatology-special-theme-issue-on-teledermatology/2461734/JMIR Dermatology—the official journal of the International Society of Teledermatology (ISTD)—and the journal’s guest editors welcome submissions to
- FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with DEBhttps://practicaldermatology.com/news/fda-approves-first-topical-gene-therapy-for-treatment-of-wounds-in-patients-with-deb/2461732/The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) g
- SCALE News: Optimize Your Results with Radiofrequency Microneedlinghttps://practicaldermatology.com/news/radiofrequency-microneedling-optimize-your-results-1/2461731/For optimal results when treating patients with radiofrequency (RF) microneedling, anecdotal and personal experience guide Elizabeth L. Tanzi, MD, as there are “no significant comparison studies to date” on the
- AI In Action: Machine Learning Algorithms May Aid Diagnosis and Treatment of ADhttps://practicaldermatology.com/news/ai-in-action-machine-learning-algorithms-may-aid-diagnosis-and-treatment-of-ad/2461726/Researchers have developed six relatively stable and reliable diagnosis and efficacy evaluation prediction models for atopic dermatitis (AD) based on a machine learning algorithm. Songjiang Wu, a PhD candidate in dermatology from Third Xiangya Hospital at the Central South University in
- Skinvive by Juvéderm Scores FDA Nod to Improve Skin Smoothness in Cheekshttps://practicaldermatology.com/news/skinvive-by-juvederm-scores-fda-nod-to-improve-skin-smoothness-in-cheeks/2461717/The U.S. Food and Drug Administration gave its nod to Skinvive by Juvéderm to improve skin smoothness of the cheeks in adults over the age of 21. Skinvive by Juvéderm is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness availabl
- Participating in an AD Trial: Weighing What Matters Most to Patients and Parentshttps://practicaldermatology.com/news/participating-in-an-ad-trial-weighing-what-matters-most-to-patients-and-parents/2461714/Key differences exist between what adults with eczema value for themselves in clinical trial participation versus what parents find important for their kids with this chronic skin disease, according to new research from the
- Cutera Update: Agreements Made With Pura Vida and RTW; New Board Members Appointedhttps://practicaldermatology.com/news/cutera-update-agreements-made-with-pura-vida-and-rtw-new-board-members-appointed/2461712/Cutera announced that it has entered into cooperation agreements with two of its largest stockholders, Pura Vida Investments LLC and RTW Investments LP, which collectively own more than 15% of the company’s outstanding shares. Pursuant to the agreements, Cutera will appo
- LifeNet Health Acquires Bioventus's Wound Care Divisionhttps://practicaldermatology.com/news/lifenet-health-acquires-bioventuss-wound-care-division/2461711/LifeNet Health announced the expantion of its portfolio with the acquisition of Bioventus' wound care division. Financial terms of the acqusition were not disclosed. "Non-healing wounds are a modern health care crisis," LifeNet Health President an